Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire CEO: Mydayis To Be Big ADHD Drug, But No Ex-US Launch Planned (Yet)

Executive Summary

Flemming Ornskov says FDA approval of long-lasting ADHD therapy Mydayis is part of Shire's plan to dramatically increase neuroscience revenues – but it won't launch the drug outside the US for some time.

You may also be interested in...



Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol

The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.

Shire Continues To Grow HAE Franchise With Takhzyro, As Hemophilia Takes A Hit

Approved in late August, the HAE prophylaxis drug has already yielded $51m in US revenues, with EU approval expected by year-end. The HAE franchise is a growth leader for Shire, despite peaks and valleys due to supply issues.

Shire's Suitors: Takeda, Pfizer Seen As Likely To Bid; Amgen Could Enter Fray

Takeda indicates to analysts that it is warming to idea of buying Shire, but do Pfizer or Amgen make greater sense to acquire the rare disease specialist?

Related Content

Topics

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel